Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FF/UMEC/VI with connected inhaler system versus fluticasone propionate/salmeterol plus tiotropium in inadequately controlled asthma
2017-001532-19Phase 3Active
- Sponsor
- GSK
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fluticasone furoate + umeclidinium bromide + vilanterol trifenatate, salmeterol + fluticasone and tiotropium in asthma (2 arms), sponsored by GSK. Primary endpoint: Percentage of participants who have either an. Started Apr 2018; status: active.
02
Drugs
fluticasone furoate + umeclidinium bromide + vilanterol trifenatatesalmeterol + fluticasonetiotropium
03
Conditions
asthma
Beyond the preview
Go deeper on 2017-001532-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001532-19.